Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
October 26, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Quarterly Activities Report
October 25, 2022 08:00 ET
|
Immutep Limited
Media Release Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
October 05, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
October 04, 2022 08:00 ET
|
Immutep Limited
Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancerBased on the encouraging Phase II clinical data for PD-L1...
Immutep to Participate in Two Upcoming Investor Conferences
September 26, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
September 23, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
September 14, 2022 08:00 ET
|
Immutep Limited
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board
September 13, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
September 06, 2022 08:00 ET
|
Immutep Limited
Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by...
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
August 30, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...